Treatment of hyperlipidemia with a modified low density lipoprotein apheresis system with dextran sulfate

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 4, 2007, Pages 249-254

  Zhao, Yi Hua ^a   Zou, Yuan Guo ^b   Sun, Qi Jun ^b   Xi, Dai ^a   Xing, Chang Ying ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Red Cross Blood Center   (China)

Author keywords

Calcium; Centrifugation; Dextran sulfate; Hyperlipidemia; Low density lipoprotein apheresis

Indexed keywords

CALCIUM CHLORIDE; DEXTRAN SULFATE; DIALYSIS FLUID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; APHERESIS; ARTICLE; CATION EXCHANGE; CENTRIFUGATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIALYSATE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PLASMA TRANSFUSION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD COMPONENT REMOVAL; DEXTRAN SULFATE; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSORBENT TECHNIQUES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 34547220327     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00487.x     Document Type: Article

References (15)

1. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975 1 : 1208 11.
2. Bosch T. Lipid apheresis: from a heroic treatment to routine clinical practice. Artif Organs 1996 5 : 414 19.
3. Barter PJ. Coronary plaque regression: role of low density lipoprotein-apheresis. J Am Coll Cardiol 2002 40 : 228 30.
4. Bambauer R, Schiel R, Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. Ther Apher 2000 4 : 213 17.
5. Uauy R, Zwiener RJ, Phillips MJ et al. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis. J Pediatr 1992 20 : 892 8.
6. Ministy of Public Health PRC. Operation Instructions for Clinical Examinations in China. Nanjing : Southeast University Press, 1998 25 6, 30 31, 237 8.
7. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976 69 : 570 77.
8. Russell Warnick G, Benderson J, John J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982 28 : 1379 86.
9. Kim YC, Nishida T. Nature of the interaction of dextran sulfate with high and low density lipoproteins in the presence of Ca2+. J Biol Chem 1979 19 : 9621 6.
10. Seidel D, Armstrong VW, Schuff-werner P, Eisenhauer T. Removal of low-density lipoproteins (LDL) and fibrinogen by precipitation with heparin at low pH: clinical application and experience. J Clin Apher 1988 4 : 78 81.
11. Gordon B, Saal S. Low-density lipoprotein apheresis using the liposorber dextran sulfate cellulose system for patients withhypercholesterolemia refractory to medical therapy. J Clin Apher 1996 11 : 128 31.
12. Bosch T, Lennneitz A, Kordes B et al. Low density lipoprotein hemoperfusion by direct adsorption of lipoprotein from whole blood (DALI apheresis): clinical experience from a single center. Ther Apher 1999 3 : 209.
13. Suzuki K, Hashimoto S. Effect of dextran sulfates on thrombin active. J Clin Pathol 1979 32 : 439 44.
14. Jiang Y-M, Chen S-R, Ma E-P et al. Studies on relationship between the toxicity and sulphur content of hemaopoietic stem cell mobilizer dextran sulphate. J Exp Hematol 1995 3 : 74 7.
15. Kroon AA, Mol MJTM, Stalenhoef AFH. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption. Lancet 1992 340 : 1476 7.